Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 913-923

  Lanas, A ^a   Ortego, J ^a   Sopena F ^a   Alcedo, J ^a   Barrio, E ^b   Bujanda, L ^c   Cosme, A ^d   Bajador, E ^e   Parra Blanco, A ^f   Ferrandez, A ^a   Piazuelo, E ^a   Quintero, E ^f   Pique, J M ^g  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b Service of Medical Genetics   (Spain)

^c Hospital de San Eloy   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P53; PROTON PUMP INHIBITOR; ROFECOXIB; VASCULOTROPIN;

ADULT; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DYSPLASIA; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STAINING; STUDENT T TEST; TREATMENT DURATION;

APOPTOSIS; BARRETT ESOPHAGUS; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; SPAIN; SULFONES; TREATMENT OUTCOME;

EID: 34548301800     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03429.x     Document Type: Article

References (41)

1. Spechler S, Goyal R. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996 110 : 614 21.
2. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis 1998 16 : 63 80.
3. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002 360 : 1587 9.
4. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999 117 : 327 35.
5. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998 12 : 1063 73.
6. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase-2 expression in Barrett's esophagus and esophageal adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000 118 : 487 96.
7. Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001 121 : 1391 9.
8. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000 30 : 3 21.
9. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87 : 803 9.
10. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000 342 : 1946 52.
11. Bresalier RS, Sandler RS, Bolognese J, et al. A randomized trial of rofecoxib to prevent colorectal adenomas: The Approve trial. Gastroenterology 2005 128 (Suppl. 2 200 A-35.
12. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002 122 : 1101 12.
13. Soumaoro LT, Uetake H, Takagi Y, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006 49 : 392 8.
14. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002 123 : 60 7.
15. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988 19 : 166 78.
16. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001 32 : 368 78.
17. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994 25 : 982 93.
18. Lanas A, Royo Y, Ortego J, Molina M, Sainz R. Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology 1999 116 : 97 107.
19. Kim YJ, Romeike BF, Uszkoreit J, Feiden W. Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas. Clin Neuropathol 2006 25 : 67 73.
20. Pich A, Ponti R, Valente G, et al. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 1994 47 : 18 22.
21. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995 104 : 42 9.
22. Hepburn PJ, Glynne-Jones E, Goddard L, Gee JM, Harper ME. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 1995 27 : 196 203.
23. Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2006 23 : 997 1005.
24. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998 7 : 97 102.
25. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001 31 : 325 48.
26. olbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996 56 : 2556 60.
27. Lao-Sirieix P, Roy A, Worrall C, Vowler SL, Gardiner S, Fitzgerald RC. Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 2006 15 : 288 93.
28. Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004 10 : 4784 92.
29. Couvelard A, Paraf F, Gratio V, et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000 192 : 14 8.
30. Wu YL, Fu SL, Zhang YP, Qiao MM, Chen Y. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 2005 59 (Suppl. 2 S289 92.
31. Auvinen MI, Sihvo EI, Ruohtula T, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002 20 : 2971 9.
32. Piazuelo E, Jimenez P, Lanas A. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 2003 9 : 2267 80.
33. Vona-Davis L, Riggs DR, Jackson BJ, McFadden DW. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J Surg Res 2004 119 : 143 8.
34. Erratum in : J Surg Res 2004 120 : 326.
35. Qadri SS, Wang JH, Coffey JC, et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg 2005 79 : 990 5.
36. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004 99 : 1877 83.
37. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify high- and low-risk patients subsets. Am J Gastroenterol 2000 95 : 1669 76.
38. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999 274 : 10911 5.
39. Moos PJ, Edes K, Fitzpatrick FA. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci USA 2000 97 : 9215 20.
40. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 102.
41. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007 356 : 2131 42.